Related Experiment Video

Updated: Jul 20, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

Effective blood concentration of micafungin for pulmonary aspergillosis

Sadahiko Shimoeda1, Shin Ohta, Hikaru Kobayashi

  • 1Department of Pharmacy, Nagano Red Cross Hospital, Wakasato, Nagano, Japan. sadahikoshimoeda@mail.goo.ne.jp

Biological & Pharmaceutical Bulletin
|September 2, 2006
PubMed

Insights

For effective treatment of pulmonary aspergillosis in blood disease patients, target a micafungin (MCFG) blood trough level of 5 mcg/ml or higher. This ensures rapid and safe therapeutic outcomes, minimizing risks.

Area of Science:

  • Medical Mycology
  • Pharmacology
  • Hematology

Background:

  • Pulmonary aspergillosis requires prompt treatment in blood disease patients.
  • Micafungin (MCFG) is used for aspergillosis, but optimal dosing and blood concentrations are crucial.
  • Previous studies indicated a high daily dose (≥150 mg) of MCFG is necessary.

Purpose of the Study:

  • To establish new clinical diagnostic criteria for mycosis.
  • To define MCFG therapeutic effect judgment criteria.
  • To investigate the effective blood concentration of MCFG for treating fungal infections, specifically pulmonary aspergillosis.

Main Methods:

  • Established new clinical diagnostic criteria for mycosis.
  • Defined MCFG therapeutic effect judgment criteria.
  • Measured blood trough levels of MCFG in patients with pulmonary aspergillosis and correlated them with clinical improvement.

Main Results:

  • No significant difference was found in MCFG blood trough levels across different clinical improvement ratings (markedly improved, improved, successfully prevented).
  • Average MCFG trough levels were 5.23±2.44 mcg/ml (markedly improved), 4.08±2.63 mcg/ml (improved), and 3.45±1.63 mcg/ml (successfully prevented).
  • These findings suggest a target trough level for effective treatment.

Conclusions:

  • A target blood trough level of 5 mcg/ml or higher for micafungin (MCFG) is advisable for treating aspergillosis in patients with blood diseases.
  • Achieving this level can facilitate rapid and safe treatment, potentially reducing adverse effects like liver impairment.
  • This research aids in optimizing MCFG dosing for better patient outcomes.

More Related Videos

Assessing Anti-fungal Activity of Isolated Alveolar Macrophages by Confocal Microscopy09:04

Assessing Anti-fungal Activity of Isolated Alveolar Macrophages by Confocal Microscopy

Published on: July 9, 2014

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus12:29

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus

Published on: April 19, 2017

Related Concept Videos

Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...